Early identification and assessment of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) are critical to improving the outlook for patients. Neuropsychological testing can be useful in diagnosing MCI and in tracking symptom evolution. Although no medications currently are available to prevent or cure AD, cholinesterase inhibitors and memantine have been shown to forestall deterioration. Various strategies are being investigated as mechanisms to alter the neurobiological substrates of AD. A number of biomarkers are also being evaluated for their potential in identifying and tracking the progression of AD, and in developing disease-modifying therapies. Use of biomarkers in addition to standardized assessment tests may help improve diagnostic accuracy.

To bring you up-to-date on these issues, this media-rich e-Newsletter provides clinical commentaries on improving identification and management of early-stage AD and MCI. It also includes graphics and brain images to illustrate the pathophysiology and clinical course of MCI and AD, compiled from various authoritative sources.

Date Released: February 1, 2010
Termination Date: February 1, 2012

Estimated time to complete: 45-60 minutes

Instructions for Participating in This CME Activity:

• Click “View Details and Launch” below to log on. Review the online e-Newsletter, including video and audio commentaries, or download and read the printable PDF version
• To receive CME credit, complete the evaluation form online or complete the evaluation form at the end of the printable version and return it to NCME via fax at (877) 659-1658